Profiling crystal engineered ligands for targeting treatment resistant androgen receptors
Preprint
Abstract
Prostate cancer (PCa) is one of the principal contributors to health burden in the aging male population. PCa develops through dysregulation of androgen receptor (AR) signaling pathways. Despite improvements in diagnostic techniques and interventions, no pharmacological measures with long term efficacy have been established once PCa advances to castration resistant prostate cancer (CRPC). To circumvent this issue, tetra-aryl cyclobutanes (CBs) have been proposed as structurally distinct compounds with a mechanism of action differing from traditional androgen receptor signaling inhibitor (ARSIs). Here, we apply principles of crystal engineering and solid state synthesis to expand the class of CBs through strategic derivatization. The synthesis of the CB occurs quantitatively, producing no side products and eliminating the need for product purification. We demonstrate how head-to-tail stacking interactions of halo-pyrimidine rings can be exploited to stack and align unsymmetrical alkenes to undergo [2+2] photodimerization to generate the CB in the solid state. We examine the structure-function relationships of CBs in vitro by profiling AR mediated transcriptional activity, receptor translocation, and cell viability. Moreover, we explore and identify putative binding interactions within CB/AR complexes and establish an adaptive ligand-binding potential using molecular docking platforms. In total, our data suggests that CBs have unexploited therapeutic potential in CRPC and that green chemistry and crystal engineering principles offer a unique route to generating these drug candidates.Keywords
Funding Information
- National Science Foundation (NSF DMR-2221086)
This publication has 29 references indexed in Scilit:
- Cyclobutanes in Small‐Molecule Drug CandidatesChemMedChem, 2022
- Crystal Engineering: An Outlook for the FutureAngewandte Chemie International Edition, 2018
- Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with AntiandrogensJournal of Urology, 2018
- Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201)European Urology, 2018
- Molecular Dynamics Studies on the Enzalutamide Resistance Mechanisms Induced by Androgen Receptor MutationsJournal of Cellular Biochemistry, 2017
- Molecular mechanism of R-bicalutamide switching from androgen receptor antagonist to agonist induced by amino acid mutations using molecular dynamics simulations and free energy calculationJournal of Computer-Aided Molecular Design, 2016
- Cyclobutane and Cyclobutene Synthesis: Catalytic Enantioselective [2+2] CycloadditionsAngewandte Chemie International Edition, 2015
- Androgen receptor signaling in prostate cancerCancer and Metastasis Reviews, 2014
- Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease HeterogeneityEuropean Urology, 2013
- Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancerInternational Journal of Cancer, 2002